<DOC>
	<DOC>NCT00463567</DOC>
	<brief_summary>Stage 1 of the study is designed to provide data about the risk-benefit of 4 dose regimens of indacaterol (75, 150, 300 &amp; 600 µg o.d.) in order to select two doses to carry forward into study Stage 2. Study Stage 2 will provide pivotal confirmation of efficacy, safety, and tolerability of the selected indacaterol doses in patients with COPD</brief_summary>
	<brief_title>26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Male and female adults aged ≥ 40 years, who have signed an Informed Consent Form prior to initiation of any studyrelated procedure Cooperative outpatients with a diagnosis of COPD (moderate to severe as classified by the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) Guidelines, 2005) and: Smoking history of at least 20 pack years Postbronchodilator FEV1 &lt; 80% and ≥ 30% of the predicted normal value. Postbronchodilator FEV1/FVC &lt; 70% (Post refers to within 30 min of inhalation of 400 µg of salbutamol) Pregnant or lactating females Patients who have been hospitalized for a COPD exacerbation in the 6 weeks prior to Visit 1 or during the runin period Patients requiring long term oxygen therapy (&gt; 15 h a day) Patients who have had a respiratory tract infection 6 weeks prior to V1 (with further criteria) Patients with concomitant pulmonary disease, pulmonary tuberculosis, or clinically significant bronchiectasis Patients with a history of asthma (with further criteria) Patients with Type I or uncontrolled Type II diabetes Patients with contraindications for tiotropium Patients who have clinically relevant laboratory abnormalities or a clinically significant abnormality Any patient with active cancer or a history of cancer with less than 5 years disease free survival time Patients with a history of long QT syndrome or whose QTc interval is prolonged Patients with a hypersensitivity to any of the study drugs or drugs with similar chemical structures Patients who have had treatment with the investigational drug (with further criteria) Patients who have had live attenuated vaccinations within 30 days prior to visit 1, or during runin period Patients with known history of non compliance to medication Patients unable to satisfactorily use a dry powder inhaler device or perform spirometry measurements Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>indacaterol</keyword>
	<keyword>long acting beta-2 agonist</keyword>
</DOC>